Monitoring the quality of laboraties and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000 by G. Migliori et al.
Monitoring the quality of laboratories and the prevalence of
resistance to antituberculosis drugs: Italy, 1998–2000
G.B. Migliori*, R. Centis*, L. Fattorini#, G. Besozzi},z, C. Saltini§, G. Orefici#, C. Piersimoniƒ,
A. Gori**, A. Cassone#, and the Italian Multicentre Study on Resistance to Antituberculosis drugs
(SMIRA) Study Group
Monitoring the quality of laboratories and the prevalence of resistance to
antituberculosis drugs: Italy, 1998–2000. G.B. Migliori, R. Centis, L. Fattorini,
G. Besozzi, C. Saltini, G. Orefici, C. Piersimoni, A. Gori, A. Cassone, and the Italian
Multicentre Study on Resistance to Antituberculosis drugs (SMIRA) Study Group.
#ERS Journals Ltd 2003.
ABSTRACT: In 1998 a network of 20 regional tuberculosis (TB) laboratories (the
Italian Multicentre Study on Resistance to Antituberculosis drugs (SMIRA) network)
was established in Italy to implement proficiency testing and to monitor the prevalence
of drug resistance nationwide. The network managed 30% of all TB cases reported in
Italy each year.
The aim of the present report is to describe: 1) the accuracy of drug-susceptibility
testing in the network; 2) the prevalence of drug resistance for the period 1998–2000.
Data were collected from the network laboratories. Sensitivity to streptomycin and
ethambutol increased from the first survey (1998–1999) to the second survey (2000)
from 87.7 to 91.9%. Specificity, predictive values for resistance and susceptibility,
efficiency and reproducibility were consistent in both surveys. In previously untreated
cases, the prevalence of multidrug-resistance was the same in both surveys (1.2%), while
a slight decrease from the first to the second survey was observed for monoresistance to
rifampicin (from 0.8 to 0.4%) and isoniazid (from 2.9 to 2%).
The significant association found between isoniazid resistance and immigration is a
useful indicator for both clinicians managing individual tuberculosis cases and public
health services planning control strategies.
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Multidrug resistance is a substantial threat both in
terms of public health (tuberculosis (TB) control) [1]
and in the clinical management of individual cases.
Multidrug-resistant TB is difficult to cure as the drugs
required for treatment are more expensive and fre-
quently cause severe side-effects [2].
A global project on antituberculosis drug-resistance
surveillance, aimed at measuring the prevalence of anti-
TB drug resistance using standardised methods, was
launched by the World Health Organization (WHO)
and the International Union Against Tuberculosis
and Lung Disease (IUATLD) [3]. The project was
based on three main principles: 1) adequate sample
representative of the population under study; 2) dis-
crimination of drug resistance between never and
previously treated cases; 3) proper laboratory perfor-
mance. In order to adhere to the international recom-
mendations [4, 5], the Italian Ministry of Public
Health established a network of regional laboratories
(Italian Multicentre Study on Resistance to Anti-
tuberculosis drugs (SMIRA) Project) to fulfil all require-
ments for participation to the WHO/IUATLD Global
Project on Drug Resistance Surveillance.
The aim of the present report is to describe: 1) the
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accuracy of drug susceptibility testing in the estab-
lished network of TB laboratories [6]; 2) the pre-
valence of drug resistance for the period 1998–2000.
Methods
Proficiency testing
Study design. All definitions were derived from the
WHO/IUATLD Global Project on Drug Resistance
Surveillance [3, 6]. Multidrug resistance was defined as
resistance to at least isoniazid and rifampicin. Drug
resistance among new cases (or previously untreated
cases or cases with no history of previous treatment)
is defined as the presence of resistant strains of
Mycobacterium tuberculosis in TB cases where TB
drugs have never been given or have been administered
forv1 month of treatment. An immigrant is defined as
a person born in another country [3–6].
In 1998 the Dept of Bacteriology and Medical
Micology of Istituto Superiore di Sanita` in Rome, was
appointed as the Supranational Reference Laboratory
and Istituto Villa Marelli in Milan, as the National
Reference Laboratory. The same batch of strains
provided by the WHO/IUATLD coordinating centre
in Ottawa, Canada, was used for proficiency testing.
The Supranational Reference Laboratory sent the
strains to the national Reference Laboratory, and the
National Reference Laboratory to the 20 regional
laboratories. As an official register of the laboratories
and TB units performing the drug susceptibility
testing does not exist in Italy, a convenience sampling
was done. The network of 20 regional mycobacteri-
ology laboratories and 46 clinical units (SMIRA),
covering 30% of the confirmed TB cases notified every
year [7], was used to reach the sample size planned
(n=750 patients) [6]. Two surveys of proficiency testing
were organised in 1998 and 1999, preced-
ing the prevalence study, performed in 1998–1999
(the first survey from April 1st, 1998–April 1st, 1999)
and in 2000 (second survey from January 1st–
December 31st). Human immunodeficiency virus
(HIV) serology was performed (with informed con-
sent) in the presence of a risk behaviour and/or signs
and symptoms suggestive of HIV infection (inclu-
ding low-grade fever, weight loss, presence of oral
thrush, etc.).
Laboratory methods. Participating laboratories used
the drug-susceptibility testing (DST) method with
which they were most familiar within the four methods
recommended by WHO in both proficiency testing
surveys [3, 6]: 1) the absolute concentration method [8];
2) the resistance-ratio method [8, 9]; 3) the proportion
method and its variants [3, 8]; 4) the BACTEC 4601
radiometric method (Becton Dickinson, Towson, MD,
USA) [9, 10]. In addition, the Mycobacteria Growth
Indicator Tube (MGIT) method (Becton Dickinson)
was used [11, 12]. Among the laboratories reporting
results by the proportion method, all used Lowenstein-
Jensen medium either self-prepared or purchased from
commercial sources [6]. Ten pairs of cultures of M.
tuberculosis were sent to the regional laboratories by
the National Reference Laboratory. The sample size
was calculated to yield a significance level of a=0.05 to
be able to detect a true difference between laboratory
methods with a power of 90% [13]. In order to maintain
confidentiality, each laboratory was identified by a
letter of the alphabet.
Dataanalysis. ThestandardisedWHOformsforrecord-
ing and reporting data were used [3, 14]. Cultures were
classified as resistant or susceptible [3, 14]. Results were
compared to the gold standard, represented by the judi-
cial results of the WHO/IUATLD Global Network of
Supranational Laboratories (agreement of the majo-
rity of Supranational Reference Laboratories) [13]. A
laboratory was considered validated for any given drug
when no more than two results were different from
the gold standard. The results were evaluated by the
following parameters: sensitivity (ability to detect true
resistance), specificity (ability to detect true suscep-
tibility), predictive values for resistance (the rate of true
resistances to total resistance) and for susceptibility (the
rate of true susceptibility to total susceptibility) and
efficiency (fraction of the number of correct results and
the total number of results) and the overall intralabo-
ratory reproducibility (or reliability) between duplicate
cultures expressed as per cent agreement [13, 14].
Prevalence survey
All consecutive confirmed (culture positive) cases
diagnosed in the TB laboratories in the two periods
mentioned above were enrolled. When the previous
treatment status was unknown or dubious, patients
were excluded. Resistant cases with and without a
previous treatment history were stratified using the
following categories: any resistance; monoresistance;
isoniazid plus rifampicin resistance; isoniazid plus
other nonrifampicin resistance; rifampicin and other
nonisoniazid resistance; other multiresistance; any
isoniazid and rifampicin resistance. The pattern of
drug resistance was also stratified by age, sex, country
of birth and HIV status. The 95% confidence intervals
(CI) were calculated.
Results
Proficiency testing
Twenty-two laboratories participated in the first
survey and 20 in the second. In the first survey,
nine (41%) laboratories used the proportion method,
nine (41%) used the BACTEC 4601 radiometric and
four (18%) the MGIT method. In the second survey,
seven (35%) laboratories used the proportion method,
10 (50%) the BACTEC 4601 radiometric and three
(15%) the MGIT method. In the first survey, 19 of 22
(86%) laboratories were validated for isoniazid and
rifampicin and 15 (68%) achieved validation for all
four drugs tested. In the second survey, 18 out of 20
laboratories (90%) were validated for isoniazid and
rifampicin and 13 (65%) for all drugs tested. The
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results of the proficiency testing exercises are sum-
marised in table 1. All parameters concerning the key
drugs (rifampicin and isoniazid) remained constantly
high or even improved from the first to the second
survey. Furthermore, sensitivity for streptomycin and
ethambutol increased, respectively, from 87.7 to 91.9%,
and from 85.5 to 88.8%, with a minimum value
increasing from 20 to 75% for streptomycin and from
0 to 17% for ethambutol.
Prevalence survey
The prevalence of drug resistance detected in
1998–1999 and 2000 is summarised in table 2. In
subjects with no history of previous treatment, the
prevalence of resistance to isoniazid was 2.9% in the
first and 2.0% in the second survey, to rifampicin 0.8%
and 0.4% respectively, while that to isoniazid plus
rifampicin (multidrug resistance) was 1.2% in both
Table 1. – First and second survey of proficiency testing in Italy (1998–1999 and 2000 respectively)
Drug First survey, 1998/1999 Second survey, 2000
Value Min Max Value Min Max
INH
Sensitivity 93.2 29 100 96.3 56 100
Specificity 98.5 100 100 98.8 75 100
PVR 99.0 93 100 99.7 94 100
PVS 91.0 38 100 92.5 36 100
Efficiency 94.8 50 100 96.8 65 100
Reproducibility 95.0 80 100 96.5 80 100
RMP
Sensitivity 94.9 70 100 94.0 50 100
Specificity 98.6 89 100 96.5 50 100
PVR 98.6 89 100 97.4 67 100
PVS 96.2 77 100 95.2 67 100
Efficiency 96.7 85 100 95.3 75 100
Reproducibility 95.1 70 100 95.5 90 100
SM
Sensitivity 87.7 20 100 91.9 75 100
Specificity 96.3 78 100 89.2 58 100
PVR 96.2 82 100 87.5 58 100
PVS 91.4 56 100 94.8 83 100
Efficiency 91.7 60 100 90.3 70 100
Reproducibility 90.6 75 100 90.5 60 100
EMB
Sensitivity 85.5 0 100 88.8 17 100
Specificity 93.8 75 100 97.5 75 100
PVR 91.4 67 100 98.5 86 100
PVS 94.1 70 100 90.6 44 100
Efficiency 91.3 70 100 92.3 50 100
Reproducibility 86.9 60 100 93.0 70 100
All data are presented as per cent. PVR: positive value of a resistant result; PVS: positive value of a susceptible result; INH:
isoniazid; RMP: rifampicin; SM: streptomycin; EMB: ethambutol.
Table 2. – Prevalence of drug resistance among tuberculosis (TB) cases never or previously treated for TB
No history of previous treatment History of previous treatment
First survey, 1998/1999 Second survey, 2000 First survey, 1998/1999 Second survey, 2000
n (%) 95% CI n (%) 95% CI n (%) 95% CI n (%) 95% CI
Total tested 683 (100) 688 (100) 115 (100) 108 (100)
Fully sensitive 599 (87.7) 85.1–90.0 610 (88.7) 86.1–90.9 44 (38.3) 29.7–47.3 57 (52.8) 43.4–62.1
Any resistance 84 (12.3) 10.0–14.9 78 (11.3) 9.1–13.9 71 (61.7) 52.6–70.3 51 (47.2) 37.9–56.6
Mono resistance 65 (9.5) 7.5–11.9 48 (7.0) 5.2–9.1 16 (13.9) 8.4–21.2 18 (16.7) 15.5–24.6
INH 20 (2.9) 1.8–4.4 14 (2.0) 1.2–3.3 6 (5.2) 2.1–10.5 6 (5.6) 2.3–11.2
RMP 6 (0.8) 0.3–1.8 3 (0.4) 0.1–1.2 5 (4.3) 1.6–9.4 6 (5.6) 2.3–11.2
SM 36 (5.3) 3.8–7.1 27 (3.9) 2.6–5.6 5 (4.3) 1.6–9.4 5 (4.6) 1.7–10.0
EMB 3 (0.4) 0.1–1.2 4 (0.6) 0.2–1.4 0 (0.0) 0.0–2.5 1 (0.9) 0.0–4.5
INHzRMP resistance 8 (1.2) 0.5–2.2 8 (1.2) 0.5–2.2 42 (36.5) 28.1–45.6 26 (24.1) 16.7–32.8
Any INH resistance 38 (5.6) 4.0–7.5 44 (6.4) 4.7–8.4 53 (46.1) 36.8–55.6 39 (36.1) 27.5–45.5
Any RMP resistance 15 (2.2) 1.3–3.5 11 (1.6) 0.8–2.8 55 (47.8) 38.8–56.9 32 (29.6) 21.6–38.7
INH: isoniazid; RMP: rifampicin; SM: streptomycin; EMB: ethambutol.
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surveys. The decrease in prevalence of rifampicin and
isoniazid resistance observed between the first and the
second survey was not statistically significant. The
results obtained by stratifying TB cases by country of
birth are summarised in table 3. In the second survey,
the prevalence of resistance to mono-isoniazid (rela-
tive risk (RR) 1.89; 95% CI 1.34–2.67; p=0.01) and to
any isoniazid (RR 1.52; 95% CI 1.16–2.01; pv0.01)
but not to rifampicin, was higher in immigrants than
in native Italians (as observed in the first survey). No
difference was found when stratifying prevalence data
by age, sex and HIV status. In cases with previous treat-
ment, a statistically significant decrease was observed
from the first to the second survey for multidrug
resistance (from 36.5 to 24.1%; RR 0.72; 95% CI
0.52–1.01; pv0.05), for any resistance (from 61.7% to
47.2%; RR 0.74; 95% CI 0.57–0.97; p=0.029) and for
any rifampicin resistance (from 47.8% to 29.6%; RR
0.66; 95% CI 0.48–0.90; pv0.01).
Discussion
In the context of consistent results in the two
proficiency testing surveys, the prevalence results
indicate a stable prevalence of anti-TB drug resistance
in the country, over the 3-yr study period.
Under a methodological perspective, the sample size
was reached correctly in both surveys. Furthermore, the
consistency of the results among newly diagnosed cases
being an indicator of "low result variability", the esti-
mates obtained were reliable, although a conve-
nience sampling was used. In fact, due to the lack of
a national list of laboratories and TB units, it is not
currently feasible to randomise the units involved in
the survey [6, 7].
Proficiency testing
The proficiency test results, achieved by regional
laboratories of a single country, are similar to those
achieved by the Global Network of Supranational
Reference Laboratories [3]. A relevant issue discussed
elsewhere [6] was the low sensitivity results for etham-
butol and streptomycin, due to the different critical
concentrations used for BACTEC and proportion
methods [6]. The second survey results indicate that
the decision of the Supranational Reference Labora-
tory and National Reference Laboratory to standar-
dise the concentration country-wide was correct. In
the second survey, the specificity values were higher
than the sensitivity ones for all drugs except strepto-
mycin (table 2). The panel of strains used, had more
resistant than susceptible strains to isoniazid (16
resistant, four susceptible), rifampicin (10 resistant)
and ethambutol (12 resistant), while streptomycin had
more sensitive than resistant strains (eight resistant, 12
sensitive). This was apparently the opposite that could
be expected [6]. Efficiency values were consistently
higher for rifampicin and isoniazid than for strepto-
mycin and ethambutol. With the exception of the
predictive value for resistance of streptomycin, the
predictive values for resistance and susceptibility were T
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consistently higher than 90% in the second survey,
suggesting that the Italian Network is presently gene-
rating reliable drug susceptibility testing results, in
terms of capacity of detecting true resistance and
susceptibility to the four first line anti-TB drugs.
Prevalence survey
From the public health prospective, the study results
indicate a consistently low prevalence of resistance
to isoniazid, rifampicin and of multidrug resistance
among new cases in the period evaluated and a sta-
tistically significant downward trend in the prevalence
of multidrug-resistant tuberculosis among previously
treated cases [15]. Resistance to isoniazid was sig-
nificantly associated with immigration from high pre-
valence countries where isoniazid has been extensively
used in the past. This finding is relevant to practicing
physicians, as it will help with the identification of
subjects at high risk of isoniazid resistance hence
allowing for the prescription of the proper treatment
regimen. It is also useful for public health planners, as
immigrants from endemic areas contribute significantly
to the fraction of new tuberculosis cases in the country
(28.2% in 1998) [5, 7]. Last, but not least, the finding
that multidrug-resistant tuberculosis is still observed
in 36.5% (first survey) and 24.1% (second survey) of
previously treated tuberculosis cases, calls for immedi-
ate public action on treatment result control.
The SMIRA Network based in Italy is
composed of: C. Piersimoni (Ancona), A. De
Santis (Bari), V. Giorgio (Bari), P. Vinciguerra
(Bari), G. Angarano (Bari), L. Petrozzi (Bari),
D. Costa (Bari), F. Gozzellino (Biella),
A. Perboni (Biella), D. Marchetti (Bologna),
M.L. Moro (Bologna), A. Pascali (Bologna),
F. Falcone (Bologna), V. Mariano (Bologna),
F. Rizza (Bolzano), P. Pretto (Bolzano),
A. Turano (Brescia), A. Matteelli (Brescia), G.P.
Carosi (Brescia), S. Tedoldi (Brescia), G. Pinsi
(Brescia), A.G. Farris (Cagliari), B. Farris
(Cagliari), A. Spanevello (Cassano Murge),
C. Foschi (Cesena), G. Trucco (Costarainera),
S. Aiolfi (Crema), T. Ceruti (Cremona),
M. Parpanesi (Cremona), S. Calabro (Feltre),
G. Felisatti (Ferrara), E. Tortoli (Firenze),
S. Nutini (Firenze), G. Montini (Forlı`),
F. Fiorentini (Forlı`), V. D9Ambrosio (Gallarate),
A. Ceraminiello (Lodi), S. Bernorio (Lodi),
L. Buono (Matera), P. Montesano (Matera),
E. Vinci (Mesagne), E. Sabato (Mesagne),
S. Gamba (Miazzina), P. Crepaldi (Miazzina),
A. Gori (Milano), LR Codecasa (Milano),
F. Mandler (Milano), V. Penati (Milano),
P. Vaccarino (Milano), C. Saltini (Roma),
G. Bertoli (Modena), F. Rupianesi (Modena),
M. Losi (Modena), L. Richeldi (Modena),
G. Ferrara (Modena), E. Minuccio (Napoli),
G. Napolitano (Napoli), G.L. Molinari (Novara),
L. Saini (Novara), A. Garzone (Novara),
C. Vertuccio (Nuoro), S. Marcias (Oristano),
M. Menozzi (Palermo), P. Marone (Pavia),
V. Peona (Pavia), C. Nascimbene (Pavia),
A. Pasi (Pavia), A. Cascina (Pavia), L. Casali
(Perugia), A. Monaco (Perugia), S. Pauluzzi
(Perugia), O. Penza (Perugia), M.B. Pasticci
(Perugia), F. Bistoni (Perugia), T. Sposini
(Perugia), V. Colorizio (L9Aquila), P. Bottrighi
(Piacenza), A. Orsi (Piacenza), L. Schiavi
(Piacenza), G. Macor (Pinerolo), G. Moretti
(Pinerolo), R. Fatigante (Potenza), A. Barbaro
(Reggio Calabria), G. Agati (Reggio Calabria),
F. Zaccara (Rho), S. Viola (Rho), R. Le
Donne (Rieti), G. Farinelli (Rieti), D. Mancini
(Rieti), M. Ermeti (Rimini), G. Orefici
(Roma), E. Iona (Roma), M. Tronci (Roma),
A. Bisetti (Roma), A. Altieri (Roma),
A. Cassone (Roma), L. Fattorini (Roma),
L. Ortona (Roma), F. Diamare (Salerno),
G. Lauriello (Salerno), G. Besozzi (Sondalo),
P. Troupioti (Sondalo), G. Cicchitto (Sondalo),
G. Di Pisa (Sondalo), S. De Lorenzo (Sondalo),
P. Ferranti (Terni), L. Fabbro (Torino),
M. Cavallero (Torino), M. Bugiani (Torino),
D. Cirillo (Torino), G. Castiglioni (Tradate),
R. Centis (Tradate), L. D9Ambrosio (Tradate),
G.B. Migliori (Tradate), M. Neri (Tradate),
A. Mottola (Treviso), M. Confalonieri (Trieste),
C. Scarparo (Vicenza), O. Armignacco (Viterbo),
L. Barelle (Vittorio Veneto), S. Nardini
(Vittorio Veneto), G. Bazzerla (Vittorio Veneto).
Members of the SMIRA Coordinating Com-
mittee: Scientific Chairman: A. Cassone
(Roma); Coordinator: G.B. Migliori (Tradate);
Members: L. Fattorini (Roma), G. Orefici
(Roma), G. Besozzi (Sondalo), C. Piersimoni
(Ancona), C. Saltini (Roma), C. Scarparo
(Vicenza), A. Gori (Milano), D. Cirillo
(Torino).
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